Sofinnova Partners led a $105m Series B round in Purespring Therapeutics.

Sofinnova Partners, an independent venture capital firm led a $105m Series B round in Purespring Therapeutics, a gene therapy company, with a focus on transforming the treatment of kidney diseases, with participation from Gilde Healthcare, Forbion, British Patient Capital and Syncona. "I’m really pleased to be able to welcome such a high-quality investor syndicate to support Purespring on this journey. Having sophisticated, experienced and committed investors on board, who understand drug development and the urgency of bringing these much-needed therapies to patients will maximise the opportunities for the company and the patients we treat,” Julian Hanak, Purespring Therapeutics, Chief Executive Officer."